Results 151 to 160 of about 50,616 (252)

Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine

Journal of Internal Medicine, Volume 300, Issue 3, Page 238-257, September 2026.
Abstract Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI).
Fredrik Piehl, Gonçalo Castelo‐Branco, Maja Jagodic, Tomas Olsson   +3 more
wiley   +1 more source

Pharmacological combination of simvastatin and doxorubicin reduces tumor growth and lung metastasis in triple-negative breast cancer. [PDF]

Front Cell Dev Biol
Llaguno-Munive M, Hernández-Hernández W, Solano-Ibañez E, Ramos-Godínez MDP, Méndez-Bernal A, Jurado R, Muñoz-Bello JO, Garcia-Lopez P.   +7 more
europepmc   +1 more source

Anti‐inflammatory agents in atherosclerosis—and a need for reform: Extraordinary claims require extraordinary evidence

Journal of Internal Medicine, Volume 300, Issue 3, Page 258-283, September 2026.
Abstract Since 1858, human atherosclerotic plaques have been shown to contain immune cells. But are these cells suitable therapeutic targets? Dozens of clinical trials of anti‐inflammatory agents other than colchicine have been performed in patients with clinically evident atherosclerosis.
Kevin Jon Williams
wiley   +1 more source

Simvastatin Mitigates Kidney Injury via Inhibition of the TNF-α/α-SMA Signaling Pathway in a Subtotal Nephrectomy Model. [PDF]

J Exp Pharmacol
Cahyawati PN, Sintya E, Aryastuti AASA, Lestarini A, Permatananda PANK.   +4 more
europepmc   +1 more source

Effect of simvastatin on Staphylococcus aureus biofilm

, 2013
Staphylococcus aureus biofilm is responsible for two-thirds of infections resulting from surgical implants. Simvastatin is a statin drug used to reduce low-density lipoprotein cholesterol levels, but has been shown to inhibit S. aureus invasion into host
Cordero, Diana
core  

Autophagy in MASLD: A Metabolic and Precision Medicine Perspective

Liver International, Volume 46, Issue 9, September 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver condition worldwide and a major contributor to cirrhosis and hepatocellular carcinoma (HCC). While metabolic triggers such as obesity and insulin resistance are key drivers of MASLD, growing evidence has identified defects in intracellular quality
Alessandra Cazzaniga, Silvia Frigo, Alessandro Cherubini, Eniada Rrapaj, Luca Valenti   +4 more
wiley   +1 more source

Antineoplastic Activity of the Combination Loratadine-Simvastatin-Gefitinib in HPV-Positive Cervical Cancer Cells: In Vitro and In Vivo Studies. [PDF]

Cancers (Basel)
Raya-Bahena T, Rivera-Escobar RM, Hernández-Gallegos E, Jiménez-Salazar JE, Damián-Matsumura P, García-Quiroz J, Camacho J.   +6 more
europepmc   +1 more source

Impact of adsorption-based solidification on the pharmaceutical performance and antidyslipidemic efficacy of simvastatin-ezetimibe SNEDDS. [PDF]

Int J Pharm X
Priani SE, Sopyan I, Chaerunisaa AY, Wilar G.   +3 more
europepmc   +1 more source

RAS/MAPK pathway modulation with simvastatin in children with Noonan syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. [PDF]

EClinicalMedicine
Edouard T, Capri Y, Verloes A, Amouroux C, Bournez M, Bretones P, Coutant R, Houang M, Amsellem Jager J, de Kerdanet M, Lacombe D, Lefevre C, Netchine I, Nicolino M, Pigeon Kherchiche P, Reynaud R, Rossi M, Berot A, Van Gils J, Willems M, Kieffer I, Dulac Y, Prickett T, Espiner E, Gennero I, Auriol F, Lepage B, Yart A.   +27 more
europepmc   +1 more source

Efficacy of simvastatin as adjunctive therapy in liver cirrhosis: an updated meta-analysis of randomized controlled trials. [PDF]

Ann Med Surg (Lond)
Iqbal Khan MF, Afridi Z, Haris Khan M, Zahid Anwar M, Nawaz A, Malik U, Usama Nawaz M, Sheheryar M, Hamad Ali M, Habib H, Siddique Karimi M, Ali F, Ahmad S, Faraz F, Sahak S.   +14 more
europepmc   +1 more source